 GSK PLC LSE:GSK, NYSE:GSK has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is paying Spero Therapeutics Inc an initial US66mln to licence the latters tebipenem pivoxil hydrobromide, which is about to enter phase III clinical trials. 